Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

STORY: Novo Nordisk is to collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy.Under the deal to start on July 1st, cash-paying patients can access a month's supply of ...

The increasing demand for weight-loss jabs such as Mounjaro and Wegovy has helped sales at the firm behind Chemist4U almost ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, ... to make more than $700 million this year on weight-loss services, a target that could be difficult to reach without Wegovy sales.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

The count-down's on for New Zealand chemist sales of weight-loss drug Wegovy. A pharmacist has told our newsroom the ...

Supermarkets are selling fewer groceries thanks to an uptick in Brits taking weight-loss drugs including Wegovy and Mounjaro, ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...